Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

Laboratory Corporation of America Holdings / Equity Bottom-Up

Laboratory Corporation of America Holdings

<ul><li>Laboratory Corporation of America Holdings (LabCorp) has seen significant growth in its first quarter of 2024 and continues to show promise for the rest of the year.</li><li>The total revenue for the quarter was $3.2 billion with adjusted earnings per share at $3.68, which represents a 5% increase in enterprise revenue from the first quarter of 2023.</li><li>Within the revenue growth, the Diagnostic Laboratories business accounted for a 4% increase, while Biopharma revenue rose 8%.</li></ul>

Laboratory Corporation of America Holdings (LabCorp) has seen significant growth in its first quarter of 2024 and continues to show promise for the rest of the year.The total revenue for the quarter was $3.2 billion with adjusted earnings per share at $3.68, which represents a 5% increase in enterprise revenue from the first quarter of 2023.Within the revenue growth, the Diagnostic Laboratories business accounted for a 4% increase, while Biopharma revenue rose 8%.

Laboratory Corporation of America (LabCorp): Will The Acquisition of Invitae Be A Game Changer? - Major Drivers

<ul><li>Laboratory Corporation of America Holdings' Q4 2023 highlighted a robust performance, driven by strong base business revenue growth.</li><li>Discussing Q4 results, revenues reached $3 billion, adjusted earnings per share was $3.30, and free cash flow from operations, excluding spin-related items, was $422 million.</li><li>Enterprise revenue grew by 4% compared to Q4 2022, led by an 8% growth in the Diagnostics business and 7% growth in the Biopharma business.</li></ul>

Laboratory Corporation of America Holdings' Q4 2023 highlighted a robust performance, driven by strong base business revenue growth.Discussing Q4 results, revenues reached $3 billion, adjusted earnings per share was $3.30, and free cash flow from operations, excluding spin-related items, was $422 million.Enterprise revenue grew by 4% compared to Q4 2022, led by an 8% growth in the Diagnostics business and 7% growth in the Biopharma business.

Laboratory Corporation of America (LabCorp): Significant Growth Momentum In The Diagnostics & Women's Health Can Revolutionize Growth? - Major Drivers

<ul><li>Laboratory Corporation of America delivered a disappointing set of results as the company was unable to meet the revenue expectations as well as the earnings expectations of Wall Street.</li><li>Base business revenue and base business revenue of Diagnostic Laboratories grew driven by strong base business volume and Ascension.</li><li>Labcorp, a segment of the company's laboratory services business, delivered exceptional growth in its Diagnostic Laboratories and generated strong progress in Central Laboratories.</li></ul>

Laboratory Corporation of America delivered a disappointing set of results as the company was unable to meet the revenue expectations as well as the earnings expectations of Wall Street.Base business revenue and base business revenue of Diagnostic Laboratories grew driven by strong base business volume and Ascension.Labcorp, a segment of the company's laboratory services business, delivered exceptional growth in its Diagnostic Laboratories and generated strong progress in Central Laboratories.

Laboratory Corporation of America Holdings: Does It Have A Sustainable Competitive Advantage? - Key Drivers

Credit

Laboratory Corporation of America Holdings / Credit

<ul><li>Laboratory Corporation of America Holdings is a major life sciences major providing vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions.</li><li>The company has decent fundamentals and has seen particularly good revenue growth in diagnostics.</li><li>Baptista Research looks to evaluate the different credit strengths and credit risks of the company as well as a line-by-line analysis of the financial statements of the company for the past four years.</li></ul>

Laboratory Corporation of America Holdings is a major life sciences major providing vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions.The company has decent fundamentals and has seen particularly good revenue growth in diagnostics.Baptista Research looks to evaluate the different credit strengths and credit risks of the company as well as a line-by-line analysis of the financial statements of the company for the past four years.

Laboratory Corporation of America Holdings: Detailed Credit Analysis & Financial Strength Evaluation Report

<ul><li>This is our first report on a life sciences major, Laboratory Corporation of America Holdings.</li><li>The company had a mixed quarter and failed to meet the revenue expectations of Wall Street despite decent revenue growth in diagnostics.</li><li>We initiate coverage on the stock of Laboratory Corporation of America Holdings with a 'Buy' rating.</li></ul>

This is our first report on a life sciences major, Laboratory Corporation of America Holdings.The company had a mixed quarter and failed to meet the revenue expectations of Wall Street despite decent revenue growth in diagnostics.We initiate coverage on the stock of Laboratory Corporation of America Holdings with a 'Buy' rating.

Laboratory Corporation of America Holdings: Initiation of Coverage – Acquisitions

United States

Laboratory Corporation of America Holdings is a clinical laboratory company that offers clinical laboratory tests used by the medical profession in routine testing, patient diagnosis, and in the monitoring and treatment of disease. The Company develops specialty testing operations, such as oncology testing, HIV genotyping and phenotyping, diagnostic genetics and clinical trials.

Laboratory Corporation of America Holdings (LH US)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Laboratory Corporation of America Holdings (LH US)

Laboratory Corporation of America (LabCorp): Will The Acquisition of Invitae Be A Game Changer? - Major Drivers

Laboratory Corporation of America Holdings (LabCorp) has seen significant growth in its first quarter of 2024 and continues to show promise for...

Baptista Research

Laboratory Corporation of America (LabCorp): Significant Growth Momentum In The Diagnostics & Women's Health Can Revolutionize Growth? - Major Drivers

Laboratory Corporation of America Holdings' Q4 2023 highlighted a robust performance, driven by strong base business revenue growth. Discussing Q4...

Baptista Research

Laboratory Corporation of America Holdings: Does It Have A Sustainable Competitive Advantage? - Key Drivers

Laboratory Corporation of America delivered a disappointing set of results as the company was unable to meet the revenue expectations as well as...

Baptista Research

Laboratory Corporation of America Holdings: Detailed Credit Analysis & Financial Strength Evaluation Report

Laboratory Corporation of America Holdings is a major life sciences major providing vital information to help doctors, hospitals, pharmaceutical...

Baptista Research

Laboratory Corporation of America Holdings: Initiation of Coverage – Acquisitions

This is our first report on a life sciences major, Laboratory Corporation of America Holdings. The company had a mixed quarter and failed to meet...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)